Epidemiology & Risk Factors of Alzheimer Disease
Alzheimer disease (AD) is the most common cause of dementia in older adults and represents one of the greatest public health challenges of the 21st century. An estimated 6.7 million Americans and nearly 100 million people worldwide are living with AD. The incidence of dementia due to AD doubles every 5 years after age 65, and barring breakthroughs in prevention or treatment, cases in the United States are projected to double by 2050. AD is the sixth-leading cause of death in Americans and the fifth-leading cause of death in people 65 years and older — the only “top 10” cause of death that cannot yet be prevented, halted, or cured. Understanding the epidemiology and risk factor profile of AD is essential for early identification of at-risk individuals, counseling on risk reduction, and advancing population-level strategies to reduce the burden of disease.
Bottom Line
- Prevalence: 6.7 million Americans and ~100 million people worldwide have AD; prevalence rises from 5.3% (ages 65–74) to 32% (age >85)
- Age: The strongest nonmodifiable risk factor; incidence doubles every 5 years after age 65
- Sex and race: Women are disproportionately affected; Black/African American individuals have ~2× and Hispanic/Latino individuals have ~1.5× higher incidence compared with non-Hispanic White individuals
- APOEε4: The most common genetic risk factor — heterozygous carriers have ~3× risk and homozygous carriers have ~15× risk relative to ε3/ε3
- Familial AD: Autosomal dominant variants in APP, PSEN1, and PSEN2 account for <1% of cases but cause inevitable early-onset disease
- Modifiable risk factors: The 2024 Lancet Commission identifies 14 potentially modifiable factors that may collectively prevent or delay up to 45% of dementia cases
- Economic burden: Lifetime cost per patient exceeds $390,000; total annual US costs exceed $300 billion for long-term care alone
Prevalence and Incidence
AD is the most common cause of dementia in older individuals, accounting for 60–80% of all dementia cases. The relationship between AD and advancing age is striking: the prevalence of dementia due to AD climbs from 5.3% between ages 65 and 74 to 32% in individuals older than 85. In the United States, 73 million people (approximately 20% of the population) are projected to be 65 years or older by 2030, and sustained increases in the median population age are expected to double the number of AD cases by 2050.
| Age Group | Prevalence of AD Dementia | Key Epidemiologic Features |
|---|---|---|
| 65–74 years | ~5.3% | Incidence begins to rise; most cases are mild cognitive impairment or very mild dementia |
| 75–84 years | ~13–18% | Incidence doubles approximately every 5 years after age 65 |
| ≥85 years | ~32% | Highest prevalence; AD neuropathologic change reaches peak frequency in the tenth decade |
Modest reductions in age-specific prevalence have been observed in recent decades, attributable to improved educational achievement and better management of vascular risk factors. However, demographic shifts are projected to greatly outpace these gains, underscoring the need for more effective prevention and treatment strategies.
Mortality and Morbidity
AD is the sixth-leading cause of death in the United States and the fifth-leading cause of death in people 65 years and older. Beyond mortality, AD is associated with substantial morbidity, disability, and dependence. A typical 70-year-old with AD can expect to spend 40% of their remaining life with severe dementia, a stage characterized by decreasing social interactions, reduced quality of life, declining mobility, and increasing reliance on others. The Global Burden of Disease classification identifies AD as the fourth-leading cause of disability-adjusted life-years lost in people 75 years and older. The average time from diagnosis to death is commonly cited as 4–8 years.
Economic Impact
The Economic Burden of Alzheimer Disease
- Lifetime cost per patient: Estimated at >$390,000 (2022 USD)
- Unpaid caregiving: Valued at nearly $340 billion annually in the United States
- Out-of-pocket expenses: Exceed $87 billion for family caregivers — nearly double those of non-dementia care partners
- Long-term care: ~75% of patients with AD dementia aged ≥80 are admitted to nursing homes (vs. 4% of the general population)
- Medicare/Medicaid costs: Per-person payments are 3× (Medicare) and 22× (Medicaid) higher in patients with AD compared with those without AD
- Total institutional costs: At least $300 billion annually for long-term care and hospice services for people ≥65 with dementia
Nonmodifiable Risk Factors
Age
Advancing age is the greatest driver of AD risk across the population. The reasons for this association are multifactorial, incorporating age-related declines in cellular repair and mitochondrial function, increasing fragmentation of sleep (which may alter Aβ production or clearance), accumulating burden of cerebrovascular disease and atherosclerosis, and cumulative exposures to toxins and oxidative stress. These changes cumulatively promote imbalances in amyloid-beta (Aβ) production and clearance that favor Aβ accumulation and downstream neuropathologic consequences.
Sex
Patients with AD are more likely to be female. Women account for approximately two-thirds of Americans living with AD. Contributing factors include greater female longevity, potential hormonal influences (e.g., estrogen decline at menopause), and differences in the distribution of genetic and vascular risk factors between sexes.
Family History and Genetics
A positive family history is one of the strongest biological risk factors for AD after aging. Having a single first-degree relative with AD increases risk by approximately 70%; two first-degree relatives raise risk ~4-fold; and four first-degree relatives increase risk nearly 15-fold. The impact of genetics is most evident in the <1% of patients with autosomal dominant variants in APP, PSEN1, or PSEN2, or triplications of chromosome 21 (Down syndrome), which cause inevitable development of AD, often at a young age.
| Genetic Factor | Gene / Locus | Mechanism | Risk Effect |
|---|---|---|---|
| APOEε4 (heterozygous) | APOE, chromosome 19 | Reduced Aβ clearance; enhanced Aβ aggregation; accelerated tau spreading at lower amyloid levels | ~3× increased risk |
| APOEε4 (homozygous) | APOE, chromosome 19 | Same as above, dose-dependent effect | ~15× increased risk |
| APOEε2 | APOE, chromosome 19 | Neuroprotective mechanisms (details incompletely understood) | Reduced risk; later onset |
| PSEN1 mutations | PSEN1, chromosome 14 | Altered γ-secretase activity; increased Aβ42/Aβ40 ratio | Most common cause of autosomal dominant AD; onset typically 30s–50s |
| PSEN2 mutations | PSEN2, chromosome 1 | Similar to PSEN1; altered γ-secretase function | Less common; variable age of onset |
| APP mutations/duplications | APP, chromosome 21 | Increased Aβ production or altered processing | Autosomal dominant; duplications increase APP dosage |
| Trisomy 21 (Down syndrome) | Chromosome 21 triplication | Three copies of APP lead to lifelong Aβ overproduction | AD neuropathology develops early in life; high risk for later cognitive decline |
| TREM2 variants | TREM2, chromosome 6 | Impaired microglial response to amyloid; altered innate immunity | Rare variants confer OR 2–4 for AD |
APOE: The Major Susceptibility Gene
The apolipoprotein E (APOE) gene harbors the most common genetic risk factor for sporadic AD worldwide. The three major alleles — ε2, ε3, and ε4 — differ by single amino acid substitutions and have markedly different effects on AD risk. The ε3 allele is the most common (60–70% of the population) and represents baseline risk. The ε4 allele (15–25% of the general population; ~50% of AD patients) increases risk in a dose-dependent manner. The ε2 allele (5–10%) is protective and associated with later age of onset.
APOEε4 promotes reduced clearance and enhanced aggregation of Aβ in the brain through its role in lipid shuttling and Aβ transport across the blood-brain barrier. APOEε4 carriers may also experience accelerated accumulation of tau at lower amyloid levels, suggesting that this allele facilitates early tau spreading across connected brain regions in amyloid-positive patients.
Racial and Ethnic Disparities in AD Risk
- Black/African American individuals have approximately 2× higher dementia incidence compared with non-Hispanic White individuals
- Hispanic/Latino American individuals have approximately 1.5× higher dementia incidence
- The overrepresentation of modifiable risk factors (hypertension, diabetes, lower educational attainment) in these communities is a major contributor
- APOEε4 risk may be modulated by ancestry: people of African or Hispanic ancestry carrying ε4 may have lower AD risk than White populations with the same genotype
- These disparities highlight the need for population-level interventions and greater representation of diverse populations in dementia research
- Community-level factors — including access to health care, food security, and exposure to environmental toxins — also contribute to differential risk
Modifiable Risk Factors
Beyond genetics, the contribution of potentially modifiable risk factors to AD is increasingly recognized. Systematic reviews and meta-analyses suggest that nearly one-half of dementia cases worldwide could be eliminated through adequate management of modifiable risk factors. The 2024 Lancet Standing Commission on Dementia Prevention, Intervention, and Care identified 14 modifiable risk factors encountered at varying stages of life, the elimination of which may prevent or delay up to 45% of dementia cases.
| Life Stage | Risk Factor | Mechanism / Evidence | Estimated Population-Attributable Fraction |
|---|---|---|---|
| Early life | Less education (<10 years) | Reduced cognitive reserve; lower brain resilience to neuropathology | ~5% |
| Midlife | Hearing loss | Reduced auditory stimulation; social withdrawal; cognitive load reallocation | ~7% |
| Hypertension | Cerebrovascular damage; impaired Aβ clearance; white matter injury | ~2% | |
| Obesity | Chronic inflammation; insulin resistance; vascular dysfunction | ~1% | |
| Excessive alcohol (≥21 units/week) | Direct neurotoxicity; nutritional deficiency; cerebrovascular disease | ~1% | |
| Traumatic brain injury | Accelerated amyloid deposition; chronic neuroinflammation | ~3% | |
| Physical inactivity | Reduced cerebral blood flow; impaired Aβ clearance; loss of neurotrophic support | ~2% | |
| Diabetes | Insulin resistance; advanced glycation; microvascular disease | ~1% | |
| Depression | HPA axis dysregulation; hippocampal atrophy; reduced social engagement | ~1% | |
| Midlife / Late life | High LDL cholesterol | Promotes cerebral amyloid angiopathy; vascular injury | ~2% |
| Late life | Smoking | Oxidative stress; cerebrovascular disease; inflammation | ~2% |
| Social isolation | Reduced cognitive stimulation; depression; stress-related neuroinflammation | ~4% | |
| Air pollution | Neuroinflammation; oxidative damage; accelerated amyloid deposition | ~3% | |
| Late life | Vision loss | Reduced sensory input; cognitive load; social disengagement | ~2% |
The Lancet Commission Framework: Clinical Implications
- 14 modifiable risk factors have been identified across early life, midlife, and late life
- Elimination of these factors may prevent or delay up to 45% of dementia cases worldwide
- The preponderance of midlife and late-life risk factors emphasizes the role of neurologists in screening, counseling, education, and advocacy
- Vascular risk management (hypertension, diabetes, hypercholesterolemia, smoking) remains the most actionable category
- Hearing loss carries the highest individual population-attributable fraction (~7%) and is addressable through hearing aid use
- Additional risk factors across the lifespan include atrial fibrillation, cerebrovascular disease, hypothyroidism, nutritional deficits, sleep apnea, and vitamin B12 deficiency
- Risk factor reduction is especially important in communities with higher prevalence of modifiable risk factors, where disparities in dementia incidence are most pronounced
Protective Factors
Factors associated with reduced lifetime risk of AD include:
- Physical activity: Regular aerobic exercise promotes cerebral blood flow, Aβ clearance, and neurotrophic factor expression; associated with lower AD risk in prospective cohort studies
- Cognitive engagement: Higher educational attainment and lifelong intellectual activity build cognitive reserve, delaying the clinical expression of AD neuropathology
- Adequate sleep: Sleep promotes glymphatic clearance of Aβ and other metabolic waste products; disrupted sleep is associated with accelerated amyloid accumulation
- Social engagement: Maintaining social networks reduces depression and chronic stress and promotes cognitive stimulation
- Mediterranean diet: Rich in omega-3 fatty acids, antioxidants, and anti-inflammatory nutrients; associated with reduced AD risk
- Vascular risk optimization: Aggressive management of hypertension, diabetes, and hyperlipidemia in midlife is associated with lower late-life dementia risk
- APOEε2 carrier status: Associated with reduced AD risk and later age of onset; may confer neuroprotective properties
Genetic Risk Factors: A Deeper Look
Autosomal Dominant AD
Variants in APP (chromosome 21), PSEN1 (chromosome 14), and PSEN2 (chromosome 1) are associated with the inevitable development of AD, often at a young age. These variants account for <1% of all AD cases but have been critical to understanding disease pathogenesis. The shared pathobiological consequence is increased production or decreased solubility of Aβ, resulting in amyloid plaque formation — a finding that forms the foundation of the amyloid cascade hypothesis.
- PSEN1 is the most common cause of autosomal dominant AD, with neuropathologic changes emerging in asymptomatic carriers in early adulthood and a predictable age at symptomatic onset within families
- APP mutations and duplications directly increase Aβ production; individuals with Down syndrome (trisomy 21) carry three copies of APP and develop AD neuropathology early in life
- PSEN2 variants are less common and may have more variable age of onset
Common Genetic Risk Variants Beyond APOE
Genome-wide association studies have identified approximately 90 common variants across 75 loci contributing to AD susceptibility. Key genes and their implicated pathways include:
- TREM2 (innate immunity / microglial function): Rare variants confer OR 2–4 for AD; critical role in the microglial response to amyloid
- ABCA7 (lipid metabolism / phagocytosis): Stronger risk in individuals of African ancestry
- BIN1 (endocytosis / tau pathology): Also a risk locus for Lewy body dementia
- CLU (lipid metabolism / Aβ clearance): Involved in Aβ aggregation and transport
- CR1 (innate immunity / complement cascade): Supports the role of neuroinflammation in AD
Genetic Testing Considerations
- Genetic testing for APP, PSEN1, and PSEN2 is not routinely recommended for patients with typical late-onset AD presentations
- Consider testing when AD affects ≥50% of relatives across ≥2 generations, one or more first-degree relatives have early-onset AD, or symptomatic onset occurs before age 50
- APOE genotyping is not routinely performed but may be justified for risk stratification before anti-amyloid immunotherapy (lecanemab, donanemab) given the association between APOEε4 copy number and amyloid-related imaging abnormalities (ARIA)
- Genetic counseling is recommended before proceeding with testing to ensure consideration of implications for medical care, insurance, and family members
The Role of Cerebrovascular Disease
Cerebrovascular disease and AD frequently coexist, and their interaction accelerates cognitive decline. Behaviors and comorbidities that impair Aβ clearance are associated with higher AD risk, including:
- Hypertension: Promotes arteriolosclerosis and disrupts perivascular Aβ drainage
- Diabetes: Insulin resistance may impair Aβ degradation by competing for insulin-degrading enzyme
- Atherosclerosis: Disrupts arterial and venular flow, impairing Aβ clearance across the blood-brain barrier
- Cerebral amyloid angiopathy: APOEε4 promotes Aβ deposition in vessel walls, increasing hemorrhage risk and impairing vascular function
Key Points for Clinical Practice
- The typical AD patient is older (seventh decade or beyond), more likely to be female, and more likely to report a family history of dementia
- Screening for modifiable vascular risk factors (hypertension, diabetes, hyperlipidemia, smoking) is essential at every visit in patients with cognitive concerns
- Modest reductions in age-specific prevalence have been achieved through better education and vascular risk management, but demographic shifts will outpace these gains
- The overrepresentation of modifiable risk factors among Black/African American and Hispanic/Latino populations contributes to disparities in dementia incidence
- All patients presenting with cognitive concerns should be screened for reversible contributors, including depression, sleep apnea, thyroid dysfunction, vitamin B12 deficiency, and medication/substance use
Summary
AD is a prevalent, deadly, and economically devastating disease with enormous social, psychological, and financial consequences. Advancing age remains the strongest risk factor, with the incidence of dementia due to AD doubling every 5 years after age 65. Genetic factors — particularly the APOEε4 allele and rare autosomal dominant variants in APP, PSEN1, and PSEN2 — contribute substantially to individual risk. Crucially, up to 45% of dementia cases may be preventable through management of 14 modifiable risk factors spanning education, vascular health, sensory function, lifestyle, and environmental exposures. Racial and ethnic disparities in AD incidence reflect differential exposure to modifiable risk factors and underscore the need for targeted public health interventions. Neurologists play a central role in screening, counseling, and advocating for risk factor modification to reduce the growing burden of AD.
References
- Day GS. Diagnosing Alzheimer disease. Continuum (Minneap Minn). 2024;30(6, Dementia):1584-1613.
- Alzheimer's Association. 2023 Alzheimer's disease facts and figures. Alzheimers Dement. 2023;19(4):1598-1695.
- Rajan KB, Weuve J, Barnes LL, et al. Population estimate of people with clinical Alzheimer's disease and mild cognitive impairment in the United States (2020-2060). Alzheimers Dement. 2021;17(12):1966-1975.
- Livingston G, Huntley J, Liu K, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. The Lancet. 2024;404(10452):P572-628.
- Livingston G, Huntley J, Sommerlad A. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446.
- Norton S, Matthews FE, Barnes DE, Yaffe K, Brayne C. Potential for primary prevention of Alzheimer's disease: an analysis of population-based data. Lancet Neurol. 2014;13(8):788-794.
- DeMattos RB, Cirrito JR, Parsadanian M, et al. ApoE and clusterin cooperatively suppress Aβ levels and deposition: evidence that ApoE regulates extracellular Aβ metabolism in vivo. Neuron. 2004;41(2):193-202.
- Steward A, Biel D, Dewenter A, et al. ApoE4 and connectivity-mediated spreading of tau pathology at lower amyloid levels. JAMA Neurol. 2023;80(12):1295-1306.
- Lines L, Sherif N, Wiener J. Racial and ethnic disparities among individuals with Alzheimer's disease in the United States: a literature review. RTI Press. 2014;RR-0024-1412:1-30.
- Lachner C, Craver EC, Babulal GM, et al. Disparate dementia risk factors are associated with cognitive impairment and rates of decline in African Americans. Ann Neurol. 2024;95(3):518-529.
- Mayeda ER, Glymour MM, Quesenberry CP, Whitmer RA. Inequalities in dementia incidence between six racial and ethnic groups over 14 years. Alzheimers Dement. 2016;12:216-224.
- Musiek ES, Holtzman DM. Mechanisms linking circadian clocks, sleep, and neurodegeneration. Science. 2016;354(6315):1004-1008.
- Scarmeas N, Luchsinger JA, Schupf N, et al. Physical activity, diet, and risk of Alzheimer disease. JAMA. 2009;302(6):627-637.
- Scholz SW, Cobos I. Genetics and neuropathology of neurodegenerative dementias. Continuum (Minneap Minn). 2024;30(6, Dementia):1801-1822.